French Pharmaceuticals & Biotech High Growth Potential Companies

Innate Pharma

Market Cap: €142.8m

Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

Oncodesign Société Anonyme

Market Cap: €99.4m

Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups.

Aelis Farma

Market Cap: €16.8m

A clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders.

Pherecydes Pharma Société anonyme

Market Cap: €14.4m

Pherecydes Pharma Société anonyme develops antibacterial treatments based on the use of bacteriophage viruses or phages.

MedinCell

Market Cap: €424.5m

A pharmaceutical company, develops long acting injectables in various therapeutic areas in France.

Valneva

Market Cap: €450.5m

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

Sartorius Stedim Biotech

Market Cap: €15.8b

Engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide.

Eurofins Scientific

Market Cap: €8.9b

Provides various analytical testing and laboratory services worldwide.

Eurobio Scientific Société anonyme

Market Cap: €242.1m

Engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer.

Oncodesign Precision Medicine Société anonyme

Market Cap: €8.4m

A biopharmaceutical company, engages in the precision medicine business.

Boiron

Market Cap: €408.0m

Manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.

Theranexus Société Anonyme

Market Cap: €3.1m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

Inventiva

Market Cap: €257.3m

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.